Ion Channel Pharmacology

• Published in: Neurotherapeutics 2007-04, Vol.4 (2), p.184-198
• Main Authors: Conte Camerino, Diana, Tricarico, Domenico, Desaphy, Jean-François
• Format: Article
• Language: English
• Subjects: Animals; Channelopathies - drug therapy; Channelopathies - genetics; channelopathy; drug therapy; Drug Therapy - methods; Humans; ion channel; Ion Channel Gating - drug effects; Ion Channel Gating - genetics; Ion Channels - classification; Ion Channels - drug effects; Ion Channels - genetics; Mutation; neurotransmitter-gated; Pharmacogenetics; Proteins; Voltage-gated
• ISSN: 1933-7213; 1878-7479; 1878-7479
• DOI: 10.1016/j.nurt.2007.01.013

Because ion channels are involved in many cellular processes, drugs acting on ion channels have long been used for the treatment of many diseases, especially those affecting electrically excitable tissues. The present review discusses the pharmacology of voltage-gated and neurotransmitter-gated ion channels involved in neurologic diseases, with emphasis on neurologic channelopathies. With the discovery of ion channelopathies, the therapeutic value of many basic drugs targeting ion channels has been confirmed. The understanding of the genotype–phenotype relationship has highlighted possible action mechanisms of other empirically used drugs. Moreover, other ion channels have been pinpointed as potential new drug targets. With regards to therapy of channelopathies, experimental investigations of the intimate drug–channel interactions have demonstrated that channel mutations can either increase or decrease affinity for the drug, modifying its potential therapeutic effect. Together with the discovery of channel gene polymorphisms that may affect drug pharmacodynamics, these findings highlight the need for pharmacogenetic research to allow identification of drugs with more specific effects on channel isoforms or mutants, to increase efficacy and reduce side effects. With a greater understanding of channel genetics, structure, and function, together with the identification of novel primary and secondary channelopathies, the number of ion channel drugs for neurologic channelopathies will increase substantially.